
Sign up to save your podcasts
Or


In this week's episode we’ll learn more about a new risk classification scheme for use in patients with acute myeloid leukemia who are ineligible for intensive therapy, efficacy and safety of daratumumab plus chemotherapy in pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, and a blood bank-compatible method for creating genetically engineered platelets with a wide range of potential uses.
Featured Articles:
By American Society of Hematology4.1
4949 ratings
In this week's episode we’ll learn more about a new risk classification scheme for use in patients with acute myeloid leukemia who are ineligible for intensive therapy, efficacy and safety of daratumumab plus chemotherapy in pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, and a blood bank-compatible method for creating genetically engineered platelets with a wide range of potential uses.
Featured Articles:

11,147 Listeners

140 Listeners

318 Listeners

499 Listeners

75 Listeners

26 Listeners

1,157 Listeners

2 Listeners

363 Listeners

373 Listeners

1 Listeners

48 Listeners

190 Listeners

30 Listeners

4 Listeners